Looks great, costs way down sale up
Key Highlights for the Second Quarter
• Record revenue of A$3.3m (vs A$2.7 million in Q1 FY25)
• Record cash receipts of A$3.4m (vs A$2.7 million in Q1 FY25)
• Net operating cash outflows of A$2.5 million for the quarter (vs. A$4.8 million in Q1
FY25)
• Cash balance of A$17.7 million
• Annual Recurring Revenue of A$12.5 million (vs. A$11.6 million in Q1 FY25)
• SOZO Core Business TCV of A$3.2 million (vs. A$4.8 million in Q1 FY25)
• Reimbursed covered lives increased to 258.5 million up from 146.6 million reported in
Q1 FY25, with continued growth in payor coverage
• 25 states now above 80% reimbursed coverage up from 16 reported in Q1 FY25
• Lead pipeline continues to grow, +112% YOY to 622 units
- Forums
- ASX - By Stock
- IPD
- Ann: Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr
IPD
impedimed limited
Add to My Watchlist
13.8%
!
3.3¢

Ann: Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.3¢ |
Change
0.004(13.8%) |
Mkt cap ! $66.90M |
Open | High | Low | Value | Volume |
3.0¢ | 3.3¢ | 2.9¢ | $108.8K | 3.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 3.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.3¢ | 1063 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.030 |
3 | 1445672 | 0.029 |
2 | 167894 | 0.028 |
5 | 635000 | 0.027 |
5 | 1619829 | 0.026 |
Price($) | Vol. | No. |
---|---|---|
0.033 | 1063 | 1 |
0.034 | 123000 | 1 |
0.035 | 335714 | 2 |
0.036 | 250000 | 1 |
0.037 | 100000 | 1 |
Last trade - 16.19pm 27/06/2025 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online